Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021040440 - PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING NONALCOHOLIC STEATOHEPATITIS (NASH)

Publication Number WO/2021/040440
Publication Date 04.03.2021
International Application No. PCT/KR2020/011513
International Filing Date 27.08.2020
IPC
A61K 31/4439 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/205 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
A61K 31/225 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
225Polycarboxylic acids
A61P 1/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
CPC
A61K 2300/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
2300Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
A61K 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
14Quaternary ammonium compounds, e.g. edrophonium, choline
A61K 31/205
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
A61K 31/225
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
225Polycarboxylic acids
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
Applicants
  • (주)셀트리온 CELLTRION INC. [KR]/[KR]
Inventors
  • 김본중 KIM, Bon Joong
  • 남궁훈 NAMKOONG, Hoon
Priority Data
10-2019-010771330.08.2019KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING NONALCOHOLIC STEATOHEPATITIS (NASH)
(FR) COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT OU LA PRÉVENTION DE LA STÉATOHÉPATITE NON ALCOOLIQUE (SHNA)
(KO) 비알콜성 지방간염(NASH, NONALCOHOLIC STEATOHEPATITIS) 치료 또는 예방을 위한 약학 조성물
Abstract
(EN)
The present invention relates to a pharmaceutical composition for treating or preventing nonalcoholic steatohepatitis (NASH) comprising 1) a thiazolidinedione-based drug, or a pharmaceutically acceptable salt, hydride or crystal form thereof, 2) carnitine, or a pharmaceutically acceptable salt, hydrate or crystal form thereof, and 3) biphenyldimethylcarboxlate, or a pharmaceutically acceptable salt, hydrate or crystal form thereof. The composition of the present invention has an excellent effect of treating or preventing nonalcoholic steatohepatitis (NASH).
(FR)
La présente invention concerne une composition pharmaceutique pour le traitement ou la prévention de la stéatohépatite non alcoolique (SHNA) comprenant 1) un médicament à base de thiazolidinédione ou un sel, un hydrure ou une forme cristalline pharmaceutiquement acceptable de celui-ci, 2) de la carnitine ou un sel, un hydrate ou une forme cristalline pharmaceutiquement acceptable de celle-ci, et 3) du biphényldiméthylcarboxylate ou un sel, un hydrate ou une forme cristalline pharmaceutiquement acceptable de celui-ci. La composition de la présente invention a un excellent effet de traitement ou de prévention de la stéatohépatite non alcoolique (SHNA).
(KO)
본 발명은 1) 티아졸리딘디온계 약물, 이의 약제학적으로 허용되는 염, 수화물 또는 결정형, 2) 카르니틴, 이의 약제학적으로 허용되는 염, 수화물 또는 결정형 및 3) 비페닐디메틸카르복실레이트, 이의 약제학적으로 허용되는 염, 수화물 또는 결정형을 포함하는 비알콜성 지방간염(NASH) 치료 또는 예방용 약학 조성물에 관한 것으로, 본 발명의 조성물은 비알콜성 지방간염(NASH)에 대한 우수한 치료 또는 예방 효과를 갖는다.
Also published as
Latest bibliographic data on file with the International Bureau